ASSIGNMENT AND LICENSE AGREEMENT
ASSIGNMENT AND LICENSE AGREEMENT
THIS AGREEMENT (this “Agreement”) is made and entered into as of November 28, 2007, by and between Inspire Medical Systems, Inc. (“Inspire”), a Delaware corporation, and Medtronic, Inc., a Minnesota corporation (“Medtronic”).
WITNESSETH:
WHEREAS, Medtronic and Inspire have agreed that in order to enable Inspire to develop and distribute products in the Field, as defined below, on a world-wide basis, Medtronic will transfer to Inspire certain assets for Inspire’s use in connection with the Field (such transfer and related transactions between Medtronic and Inspire, to be known herein as the “Spin-Out”).
WHEREAS, in connection with the Spin-Out, Medtronic and Inspire have entered into an investment agreement of even date herewith whereby Medtronic shall make certain investments in Inspire (the “Investment Agreement”); and
WHEREAS, in connection with the Spin-Out, Medtronic agrees to assign to Inspire, the Assigned Patents (as defined herein) and Trademarks (as defined herein) and to license to Inspire the Technical Information and Licensed Patents (all as defined herein) in the Field (as defined herein), subject to the terms and conditions of this Agreement.
AGREEMENTS:
NOW THEREFORE, in consideration of the representations, warranties, covenants and agreements contained herein, and for other valuable consideration, the receipt and adequacy of which is hereby acknowledged, the parties mutually agree as follows:
ARTICLE 1
DEFINITIONS
1.1) Specific Definitions. As used in this Agreement, the following definitions and terms shall have the designated meanings:
“Affiliate” has the meaning set forth in the Investment Agreement.
“Agreement” means this Agreement and all Exhibits attached hereto.
“Assigned Patents” means (a) the patents listed on Exhibit A; and (b) all continuation, divisional , re-issue or re-examination applications that may be filed based on the patents listed on Exhibit A.
“Base IP” means Intellectual Property owned by, or licensed to (with the right to sublicense), Inspire that has application in the Field. For the avoidance of doubt, Base IP includes the Assigned Patents and the Licensed Patents.
“Closing” has the meaning set forth in the Investment Agreement.
“Confidential Information” has the meaning set forth in the Investment Agreement.
“Field” means the electrical stimulation of the upper airway for the treatment of obstructive sleep apnea.
“Grant-Back Base IP” means any Base IP that is owned by, or licensed to (with the right to sublicense), Inspire at any time during the period beginning on the Initial Closing Date and ending on the date that the Noncompetition Period ends.
“IDEA Disclosures” means the IDEA disclosures identified on Exhibit B-1.
“IDEA Disclosure Patents” means: (a) any patent applications filed by, or on behalf of, Inspire, or its Affiliates, that are based upon, or that contain subject matter that is related to the subject matter of, any IDEA Disclosures; (b) any patents which issue from any of the patent applications of subpart (a); and (c) all continuation, divisional, re-issue or re-examination applications that may be filed based on the patents and patent applications of subparts (a) and (b), together with any patents that may issue based thereon.
“Improvement Patents” means any patent or patent application included in the Base IP: (a) that claims, or could claim, priority, either directly or indirectly, from any of the patents or patent applications included in the Assigned Patents or Licensed Patents; or (b) from which any of the patents or patent applications included in the Assigned Patents or Licensed Patents claims, or could claim, priority, either directly or indirectly.
“Initial Closing Date” has the meaning set forth in the Investment Agreement.
“Insolvent” with respect to a party means that such party, makes an assignment for the benefit of creditors, files, or has filed against it involuntarily, a petition for relief under any applicable code, or goes into receivership.
“Intellectual Property” has the meaning set forth in the Investment Agreement.
“Indemnifiable Losses” has the meaning set forth in Section 5.1.
“Knowledge” has the meaning set forth in the Investment Agreement.
“L169 IC” means the integrated circuit that is assembled onto the hybrid assembly and further assembled into the 3024 Implantable Pulse Generator as defined in the Development Agreement.
“Licensed Patents” means (a) the patents and patent applications listed on Exhibit B; (b) any patents which issue from the patent applications listed on Exhibit B; (c) all continuation, divisional, re-issue or re-examination applications that may be filed based on the patents and patent applications listed on Exhibit B, together with any patents that may issue based thereon; and (d) any IDEA Disclosure Patents.
“Product Liability” has the meaning set forth in the Investment Agreement.
“Products” mean the products set forth in the Development Agreement.
“Sale Transaction” has the meaning set forth in the Investment Agreement.
“Software” means software designs necessary to drive the functions of the physician and patient programmers as well as software necessary to drive the test equipment that evaluates the functionality of the Products.
“System” means a device for use in the Field that includes a 3024 Implantable Pulse Generator (as defined in the Development Agreement), a 3063 Stimulation Lead, and a Pressure Sensor Capsule (as defined in the Development Agreement).
“Technical Information” means the information specifically set forth on Exhibit C as it relates to the 3063 Stimulation Lead, the L169 IC, and the Software, and only to the extent such information is required to develop, manufacture, and market products for use in the Field, as well as to ensure compliance to Food and Drug Administrative (FDA) Quality System Regulations and specifically, 21 C.F.R. Part 820, Sections 820.180, 820.181 and 180.184. Technical Information specifically excludes any information relating to Medtronic’s chronicle lead. All Technical Information disclosed under this Agreement shall be considered Confidential Information.
“3063 Stimulation Lead” means the stimulation lead incorporating a full cuff with three electrodes in a guarded bi-polar configuration with a lead body and connector to interface with the 3024 Implantable Pulse Generator.
“Trademarks” means the trademark and trademark applications, together with any registrations that may issue based thereon, set forth in Exhibit D.
1.2) Definitional Provisions.
(a) The words “hereof,” “herein,” and “hereunder” and words of similar import, when used in this Agreement, shall refer to this Agreement as a whole and not to any particular provisions of this Agreement.
(b) The terms defined in the singular shall have a comparable meaning when used in the plural, and vice versa. Terms referring to a masculine gender shall be deemed to refer to the feminine or neuter genders, as applicable.
(c) The term “including” is not limiting and, unless preceded by the word “not,” has the meaning “including, without limitation.”
(d) References to an “Exhibit” or to a “Schedule” are, unless otherwise specified, to one of the Exhibits or Schedules attached to or referenced in this Agreement, and references to an “Article” or a “Section” are, unless otherwise specified, to one of the Articles or Sections of this Agreement.
(e) The term “person” means any individual, partnership, firm, corporation, limited liability company, association, trust, unincorporated organization, governmental department or agency, or other entity, as well as any syndicate or group that would be
deemed to be a person under Section 13(d)(3) of the Securities Exchange Act of 1934, as amended.
(f) The term “dollars” or “$” shall refer to the currency of the United States of America.
(g) All references to time shall refer to Minneapolis, Minnesota time.
1.3) Other Terms. Other terms may be defined elsewhere in the text of this Agreement and shall have the meaning indicated throughout this Agreement.
ARTICLE 2
ASSIGNMENT AND LICENSE
2.1) Assignment. Subject to the terms and conditions of this Agreement, Medtronic hereby assigns to Inspire the Assigned Patents, the Trademarks and the goodwill associated with the Trademarks. Medtronic will execute the recordable assignment forms provided in Exhibit E on the Initial Closing Date.
2.2) Technical Information License Grant. Subject to the terms and conditions of this Agreement, Medtronic agrees to grant, and hereby grants, to Inspire a co-exclusive, worldwide, royalty-free, perpetual, irrevocable, non-sublicensable and non-transferable (except as set forth below) license to the Technical Information to make, have made, use, import, offer to sell and sell products in the Field, and to practice methods in the Field. Medtronic agrees that the co-exclusive license rights granted to Inspire under this Section 2.2 shall be exclusive to Inspire unless and until Inspire becomes Insolvent at which point Medtronic may also exercise its co-exclusive rights to practice in the Field. Inspire may not transfer Technical Information except as provided for as part of a Sales Transaction. Nothing set forth herein shall prevent Inspire from granting rights to distribute its products through all standard commercial means, including granting distribution rights to dealers, distributors, agents and other third parties who are in the business of distributing products such as those developed by Inspire.
2.3) Patent License Grant. Subject to the terms and conditions of this Agreement, Medtronic agrees to grant, and hereby grants, to Inspire a co-exclusive, worldwide, royalty-free, perpetual, irrevocable, non-sublicensable and non-transferable (except as set forth below) license to the Licensed Patents to make, have made, use, import, offer to sell and sell products in the Field, and to practice methods in the Field. Medtronic agrees that the co-exclusive license rights granted to Inspire under this Section 2.3 shall be exclusive to Inspire unless and until Inspire becomes Insolvent at which point Medtronic may also exercise its co-exclusive rights to practice in the Field. Inspire may not transfer the license granted to it under this Section 2.3 except as provided for as part of a Sales Transaction. The parties acknowledge that as part of its license grant under this Section 2.3, Inspire shall have the right, but not the obligation, to prepare and file, or have prepared and filed on its behalf, at Inspire’s sole cost, IDEA Disclosure Patents.
2.4) Co-Exclusive Licenses. The licenses granted to Inspire under Section 2.2 and Section 2.3 shall be co-exclusive licenses, meaning that Medtronic shall also have the worldwide right under the Technical Information and Licensed Patents to make, have made, use, market, import, offer for sale and sell products in the Field, and to practice methods in the Field, but
Medtronic shall not have the right to grant any further licenses to such Technical Information and Licensed Patents in the Field. Medtronic agrees that it shall not exercise its license rights in such Technical Information and Licensed Patents in the Field unless and until Inspire becomes Insolvent.
2.5) License Restrictions.
(a) During the term of the Supply Agreement, Inspire shall not exercise its rights under the license granted in Section 2.3 with respect to having Products made in the Field except as permitted under the Supply Agreement.
(b) The license granted pursuant to Section 2.3 shall not be used in such a way as to manufacture Products on an original equipment manufacturer basis (“OEM basis”) for any person or entity without the prior written approval of Medtronic, which may not be unreasonably withheld. The term “OEM basis” includes, without limitation, the manufacture and sale of a product to any person or entity for (i) incorporation into or sale with or as such other person’s or entity’s product, or (ii) the resale of such product by such person or entity under trademarks other than those owned by Inspire. It is the intent of the parties that the licenses granted herein be used for the sole and exclusive benefit of Inspire and that all licensing of third parties shall be the sole right of Medtronic in its sole and absolute discretion.
2.6) Restrictions on Use. Inspire will use reasonable efforts to ensure that all Products manufactured by or for Inspire or sold by Inspire are not used outside of the Field. Without limiting the foregoing, if Inspire has Knowledge that the manufacture, use, sale, import, or other distribution of products manufactured by or for Inspire or sold by Inspire are, or likely will be, in violation of the licenses granted herein, or if Medtronic notifies Inspire of any such violation, then Inspire shall immediately, at Inspire’s sole expense, take reasonable steps to attempt to prohibit or terminate such violation.
2.7) Medtronic Licenses to Intellectual Property.
(a) Inspire agrees to grant, and hereby grants, to Medtronic and its Affiliates an exclusive, worldwide, royalty-free, perpetual, irrevocable, sublicensable and transferable license to the Assigned Patents to make, have made, use, import, offer to sell and sell products outside of the Field, and to practice methods outside of the Field.
(b) Inspire agrees to grant, and hereby grants, to Medtronic and its Affiliates an exclusive, worldwide, royalty-free, perpetual, irrevocable, sublicensable and transferable license to any: (a) Improvement Patents; (b) Base IP covering the System; and (c) Grant-Back Base IP; each of (a), (b) and (c) to make, have made, use, import, offer to sell and sell products outside of the Field, and to practice methods outside of the Field.
(c) Inspire agrees to grant, and hereby grants, to Medtronic and its Affiliates a co-exclusive, worldwide, royalty-free, perpetual, and irrevocable license to the Assigned Patents to make, have made, use, import, offer to sell and sell products in the Field, and to practice methods in the Field. Medtronic agrees that it shall not exercise its license rights granted it under this Section 2.7(c) unless and until Inspire becomes Insolvent.
(d) Inspire agrees to grant, and hereby grants, to Medtronic and its Affiliates a co-exclusive, worldwide, royalty-free, perpetual, and irrevocable license to the Licensed Patents to make, have made, use, market, import, offer for sale and sell products in the Field, and to practice methods in the Field. Medtronic agrees that it shall not exercise its license rights granted it under this Section 2.7(d) unless and until Inspire becomes Insolvent.
(e) Inspire agrees to grant, and hereby grants, to Medtronic and its Affiliates a co-exclusive worldwide, royalty-free, perpetual, and irrevocable license to any Base IP (other than the Base IP which is licensed to Medtronic under Section 2.7(c) and 2.7(d)) to make, have made, use, import, offer to sell and sell products in the Field, and to practice methods in the Field. Medtronic agrees that it shall not exercise its license rights granted it under this Section 2.7(e) unless and until Inspire becomes Insolvent.
(f) The licenses granted to Medtronic under Sections 2.7(c), 2.7(d) and 2.7(e) shall be co-exclusive, meaning that Inspire shall also have the worldwide right to make, have made, use, market, import, offer for sale and sell products in the Field, and to practice methods in the Field, but Inspire shall not have the right to grant any further licenses to such Intellectual Property in the Field.
2.8) No Other Rights. Inspire acknowledges and agrees that, as between the parties, Medtronic owns all right, title and interest, including all Intellectual Property Rights, in and to the Licensed Patent Rights, Technical Information and Medtronic’s Confidential Information, and that under this Agreement, Inspire shall acquire no right, title, or interest in or to any of the foregoing, or to any other Intellectual Property Rights of Medtronic, by implication, estoppel or otherwise, other than the license rights expressly granted herein.
2.9) Non-Compete.
(a) Except as Medtronic is otherwise permitted or required to perform certain obligations to the benefit of Inspire as set forth herein or in any of the other agreements entered into between Medtronic and Inspire in connection with the Spin-Out (the “Spin-Out Documents”), for a period commencing on the Initial Closing Date and ending on the fifth (5th) anniversary of the Initial Closing Date (the “Noncompetition Period”), neither Medtronic nor its Affiliates shall: (i) market, sell or have sold for it a Competing Product (defined below) anywhere in the United States or in any country where Inspire conducts business; (ii) fund any clinical study that enrolls patients for the sole purpose of obtaining regulatory approval in the United States of a Competing Product for Medtronic or an Affiliate of Medtronic; or (iii) make a direct equity investment (including investment in convertible securities) in excess of One Million Dollars ($1,000,000) in Apnex Medical, any other Person that at the time of the investment markets, sells or has sold for it any Competing Product, or any other Person that at the time of the investment is solely engaged in developing a Competing Product and has enrolled patients in any clinical study for the sole purpose of obtaining regulatory approval in the United States of a Competing Product for such Person.
(b) For the purposes of this Section 2.9, a “Competing Product” shall mean a product with the primary and regulatory approved purpose of utilizing electrical stimulation of the Hypoglossal Nerve for the treatment (as opposed to diagnosis) of obstructive sleep apnea.
(c) Notwithstanding the foregoing, the restrictions in this Section 2.9 shall not apply: (i) with respect to any Person that becomes an Affiliate of Medtronic or assets that are acquired by Medtronic or an Affiliate of Medtronic after the date of this Agreement if 10% or less of the annual revenues of such Person or of revenues generated by such acquired assets relate to sales of Competing Products at the time such Person first becomes an Affiliate of Medtronic or such assets are acquired by Medtronic; (ii) from and after a Sale Transaction; and (iii) from and after the time that Inspire is Insolvent. Except as explicitly set forth in (a)(iii) above, Inspire acknowledges and agrees that the restrictions in this Section 2.10 shall not apply to any Person in which Medtronic or an Affiliate of Medtronic has an investment unless and until such Person becomes an Affiliate of Medtronic.
(d) The restrictions set forth in this Section 2.9 are for the personal benefit of Inspire only. Inspire’s rights and benefits pursuant to this Section 2.9 shall not be assignable by Inspire and any attempted assignment of Inspire’s rights and benefits under this Section 2.9 shall be void.
(e) Inpire’s sole right and remedy with respect to a violation of this Section 2.9 shall be to seek injunctive relief against Medtronic or an Affiliate of Medtronic to enjoin the activities that are in violation of this Section 2.9. In no event shall Inspire be entitled to money damages (under any theory or cause of action) from Medtronic or an Affiliate of Medtronic with respect to a violation of this Section 2.9 and Inspire hereby waives any and all rights to money damages that may result from a violation of this Section 2.9 as a result of a breach hereof by Medtronic or an Affiliate of Medtronic. Notwithstanding anything to the contrary herein, in the event any Person becomes an Affiliate of Medtronic after the date of this Agreement, or Medtronic or an Affiliate acquires assets that include Competing Products from a Person, and at such time more than 10% of such Person’s annual revenues or revenues of such Person that are generated by such acquired assets relate to sales of Competing Products (a “Prohibited Acquisition”), Medtronic shall have the right to continue to sell such Competing Products for up to 3 months after the date of the Prohibited Acquisition; provided that if Medtronic continues to sell Competing Products after such 3 month period, Inspire’s sole right and remedy shall be to require Medtronic to divest the portion of such Person or acquired assets by the date that is twelve (12) months after the date of the Prohibited Acquisition if such date is within the Noncompetition Period.
ARTICLE 3
INTELLECTUAL PROPERTY
3.1) Control of Patents by Inspire.
(a) Inspire shall have the right, through counsel of its choice and at its expense, to prepare, file and prosecute all patent applications and cause the issuance of and maintain
any patents awarded thereby worldwide (including provisionals, non provisionals, continuations, divisions, continuations in part, PCT applications, national phase applications, reissues and reexaminations) for the Assigned Patents and any IDEA Disclosure Patents. Further, Inspire shall have the right to manage any interference that might be declared with respect to the Assigned Patents and any IDEA Disclosure Patents.
(b) If Inspire does not prosecute or maintain any patent or patent application within the Assigned Patents, Inspire shall so notify Medtronic prior to any relevant deadline and Medtronic shall have the right, but not the obligation, to undertake the prosecution or maintenance of such Assigned Patents. If Medtronic exercises this option, Inspire shall assign such Assigned Patents to Medtronic and Inspire shall execute a recordable assignment form. Any such patents assigned to Medtronic will thereafter be subject to the license grant in Section 2.3.
(c) Medtronic shall have the right to review and comment on any IDEA Disclosure Patent and any filing or other correspondence related to the prosecution of any IDEA Disclosure Patent (“Patent Documents”). Inspire shall provide Medtronic with a copy of any Patent Documents that Inspire intends to file in a patent office prior to such filing (including any patent application that would be an IDEA Disclosure Patent) or that is received from a patent office. Provided that Medtronic’s comments are received within thirty (30) days following receipt of the relevant information by the Medtronic employee responsible for reviewing such Patent Documents from Inspire, Inspire shall incorporate any reasonable comments requested by Medtronic into such Patent Document.
3.2) Control of Patents by Medtronic.
(a) Medtronic shall have the right, through counsel of its choice and at its expense, to prepare, file and prosecute all patent applications and cause the issuance of and maintain any patents awarded thereby worldwide (including provisionals, non provisionals, continuations, divisions, continuations in part, PCT applications, national phase applications, reissues and reexaminations) for the Licensed Patents. Further, Medtronic shall have the right to manage any interference that might be declared with respect to the Licensed Patents.
(b) If Medtronic does not prosecute or maintain any patent or patent application within the Licensed Patents in the Field, Medtronic shall so notify Inspire prior to any relevant deadline and Inspire shall have the right, but not the obligation, to undertake the prosecution or maintenance of such Licensed Patents.
3.3) Notice of Alleged Infringement or Misappropriation. Inspire shall promptly report in writing to Medtronic during the term of this Agreement any known or suspected infringement of any of the Licensed Patents or Assigned Patents, or any misappropriation of the Technical Information by a third party. Medtronic shall promptly report in writing to Inspire during the term of this Agreement any known or suspected infringement of any of the Licensed Patents in the Field or Assigned Patents in the Field, or any misappropriation of the Technical Information in the Field by a third party.
3.4) Intellectual Property Enforcement.
(a) As between the parties hereto, Inspire reserves the right, and shall have the exclusive first right, to commence, defend, compromise, settle and control (by way of license or otherwise) (collectively, “Actions”) any and all claims, actions or proceedings for infringement, unauthorized use, misappropriation or violation of any of the Licensed Patents or Assigned Patents involving third parties (collectively, “Claims”) in the Field, but shall not have the obligation to do so. Inspire shall promptly notify Medtronic of any Action Inspire intends to take with respect to such Claim during the term of this Agreement, and Medtronic shall provide Inspire with all reasonable cooperation and assistance at Inspire’s expense. Medtronic consents to being joined as a party-plaintiff in any Action hereunder if, and to the extent, such xxxxxx is required by law for standing. If Inspire undertakes any such Action, Inspire shall be entitled to receive any recovery from the Action for damages and other awards to the extent such recovery relates to a Claim in the Field, and Medtronic shall be entitled to receive any recovery from the Action for damages and other awards to the extent such recovery relates to a Claim outside of the Field. Notwithstanding the above, Inspire shall not settle any Action if such settlement would materially adversely impact Medtronic’s rights under this Agreement.
(b) If Inspire does not undertake any Action within (90) days after notice of a Claim in the Field has been sent pursuant to Section 3.3 above, then Medtronic shall have the right to commence, defend, compromise, settle and control (by way of license or otherwise) any and all Actions with respect to such Claim, but shall not have the obligation to do so. Medtronic shall promptly notify Inspire of any Action Medtronic intends to take with respect to a Claim during the term of this Agreement and Inspire shall provide Medtronic with all reasonable cooperation and assistance at Inspire’s expense. Inspire consents to being joined as a party-plaintiff in any Action hereunder if, and to the extent, such xxxxxx is required by law for standing. If Medtronic undertakes any such Action, Medtronic shall be entitled to receive any recovery from the Action for damages and other awards to the extent such recovery relates to a Claim outside of the Field, and Inspire shall be entitled to receive any recovery from the Action for damages and other awards to the extent such recovery relates to a Claim in the Field. Notwithstanding the above, Medtronic shall not settle any Action if such settlement would materially adversely impact Inspire’s rights under this Agreement.
3.5) Trademark. Nothing in this Agreement shall confer in Inspire any rights, whether by way of ownership , license or right to use, in the trademark “Medtronic,” the Medtronic corporate logo, or any other trademark, service xxxx, trade name, trade dress, logotype or similar right owned by Medtronic or its Affiliates.
ARTICLE 4
REPRESENTATIONS & WARRANTIES
4.1) Representations of Inspire. Inspire represents, warrants and covenants to Medtronic that:
(a) Inspire has the skills and resources to conduct due diligence on Medtronic’s published patent portfolio and is entering this Agreement based on its independent evaluation thereof. Inspire acknowledges that it has studied the questions of validity and enforceability of the Assigned Patents and Licensed Patents and believes such rights to be valid and enforceable.
(b) Neither the execution and delivery of this Agreement nor the consummation of the transactions contemplated herein will violate any provision of the articles and bylaws of Inspire or any law, rule, regulation, writ, judgment, injunction, decree, determination, award or other order of any court or governmental agency or instrumentality, domestic or foreign.
4.2) Representations of Medtronic. Medtronic represents, warrants and covenants to Inspire that it has the right to grant the assignment and licenses granted under this Agreement. To Medtronic’s knowledge, as of immediately prior to the Initial Closing, Medtronic owns title to the Assigned Patents free and clear of all security interests. For purposes of clarification only, and without limiting in any way the disclaimers set forth in this Article 4, Medtronic make no representations with respect to the validity of the Assigned Patents or Licensed Patents and makes no representations with respect to non-infringement of third party proprietary rights by the Assigned Patents or Licensed Patents. OTHER THAN THE WARRANTIES EXPRESSLY GIVEN IN THIS SECTION 4.2, MEDTRONIC MAKES NO WARRANTIES, EXPRESS OR IMPLIED, WITH RESPECT TO THE ASSIGNED PATENTS, LICENSED PATENTS OR ANY PRODUCTS MANUFACTURED, USED OR SOLD (OTHER THAN AS MAY BE MADE UNDER THE SUPPLY AGREEMENT BETWEEN THE PARTIES) UNDER THIS AGREEMENT, INCLUDING WITHOUT LIMITATION, ANY WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, PATENTABILITY, PATENT VALIDITY, NON-INFRINGEMENT , OR WARRANTIES ARISING FROM COURSE OF DEALING OR USAGE OF TRADE.
4.3) Disclaimers of Representations. EXCEPT AS EXPRESSLY SET FORTH IN SECTION 4.2, EACH PARTY HERETO (AS “DISCLAIMING PARTY”) DISCLAIMS, AND THE OTHER PARTY HEREBY WAIVES, ANY AND ALL REPRESENTATIONS AND WARRANTIES, EXPRESS OR IMPLIED, ARISING BY LAW OR OTHERWISE WITH REGARD TO THIS AGREEMENT. WITHOUT LIMITING THE GENERALITY OF THE FOREGOING, THE DISCLAIMING PARTY DISCLAIMS (A) ANY AND ALL REPRESENTATIONS AND WARRANTIES, EXPRESS OR IMPLIED, REGARDING THE SCOPE, COVERAGE, VALIDITY OR ENFORCEABILITY OF ANY OF THE ASSIGNED PATENTS, LICENSED PATENTS, BASE IP AND ANY OTHER INTELLECTUAL PROPERTY RIGHTS ASSIGNED OR LICENSED HEREUNDER (COLLECTIVELY, “CONTRACT IP”); AND (B) ANY AND ALL REPRESENTATIONS AND WARRANTIES, EXPRESS OR IMPLIED, WITH REGARD TO ANY PRODUCT DEVELOPED OR
DISTRIBUTED THAT IS BASED UPON OR INCLUDES ANY CONTRACT IP (INCLUDING, BUT NOT LIMITED TO, ANY INFRINGEMENT, MISAPPROPRIATION OR VIOLATION OF ANY INTELLECTUAL PROPERTY RIGHT OF ANY THIRD PARTY AND ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE).
4.4) Limitations of Liability. IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER PARTY FOR ANY SPECIAL, CONSEQUENTIAL, INDIRECT, INCIDENTAL OR PUNITIVE DAMAGES OR LOST PROFITS OR LOST BUSINESS, HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY (INCLUDING NEGLIGENCE) ARISING IN ANY WAY OUT OF THIS AGREEMENT, WHETHER OR NOT SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
ARTICLE 5
INDEMNIFICATION
5.1) Indemnification of Medtronic. Inspire shall indemnify, defend and hold harmless Medtronic and its officers, directors, stockholders and Affiliates (such indemnitees referred to in this Article 5 as “Medtronic”) from and against and in respect of any and all demands, claims, actions or causes of action, assessments, losses, damages, liabilities, interest and penalties, costs and expenses (including, without limitation, reasonable legal fees and disbursements incurred in connection therewith and in seeking indemnification therefor, and any amounts or expenses required to be paid or incurred in connection with any action, suit, proceeding, claim, appeal, demand, assessment or judgment) (“Indemnifiable Losses”), resulting from, arising out of, or imposed upon or incurred by any person to be indemnified hereunder by reason of any of the following:
(a) Any breach of any representation, warranty, covenant or agreement of Inspire contained in this Agreement; and
(b) Any act or omission of Inspire or any of its agents, employees or suppliers arising out of or in connection with the development, commercialization, sale or other use of the Licensed Patents, Assigned Patents or any products licensed by, or developed by or for, Inspire, including but not limited to Product Liability Claim except with respect to Losses arising out of matters for which Medtronic has an obligation to indemnify Inspire pursuant to this Agreement.
5.2) Indemnification of Inspire. Medtronic shall indemnify, defend and hold harmless Inspire and each of its subsidiaries, officers, directors and stockholders (such indemnitees referred to in this Article 5 as “Inspire”) from and against and in respect of any and all Indemnifiable Losses, resulting from, arising out of, or imposed upon or incurred by any person to be indemnified hereunder by reason of any breach of any representation, warranty, covenant or agreement of Medtronic contained in this Agreement.
5.3) Third-Party Claims. If a claim by a third party is made against an indemnified party and if the indemnified party intends to seek indemnity with respect thereto under this Article 8, such indemnified party shall promptly notify the indemnifying party of such claim; provided,
however, that failure to give timely notice shall not affect the rights of the indemnified party so long as the failure to give timely notice does not adversely affect the indemnifying party’s ability to defend such claim against a third party. The indemnified party shall not settle such claim without the consent of the indemnifying party, which consent shall not be unreasonably withheld or delayed. If the indemnifying party acknowledges in writing its indemnity obligations for Indemnifiable Losses resulting therefrom, the indemnifying party may participate at its own cost and expense in the settlement or defense of any claim for which indemnification is sought.
5.4) Cooperation as to Indemnified Liability. Each party hereto shall cooperate fully with the other parties with respect to access to books, records, or other documentation within such party’s control, if deemed reasonably necessary or appropriate by any party in the defense of any claim which may give rise to indemnification hereunder.
ARTICLE 6
CONFIDENTIAL INFORMATION — INSOLVENCY
In the event that Inspire becomes Insolvent, all Confidential Information, other than the Technical Information, shall immediately be returned to Medtronic.
ARTICLE 7
OTHER PROVISIONS
7.1) Non-Disclosure. Each party agrees not to disclose or use (except as permitted or required for performance by the party receiving such Confidential Information of its rights or duties hereunder) any Confidential Information of the other party obtained during the term of this Agreement and for as long as such information is maintained as confidential by the disclosing party, but in any event, not less than a period of three (3) years after the receiving party’s receipt of such Confidential Information. Each party further agrees to take appropriate measures to prevent any such prohibited disclosure by its present and future employees, officers, agents, subsidiaries, or consultants during such period.
7.2) Complete Agreement. The Investment Agreement, the Supply Agreement, the Development Agreement, the Transaction Documents, and Exhibits to this Agreement shall be construed as an integral part of this Agreement to the same extent as if they had been set forth verbatim herein. This Agreement and the exhibits hereto constitutes the entire agreement between Inspire and Medtronic with respect to the subject matter of this Agreement and supersedes any prior agreements or understandings. This Agreement does not supersede any terms in the Development Agreement and Supply Agreement and terms in such agreements shall co-exist with this Agreement.
7.3) Survival of Representations, Warranties and Agreements. The representations, warranties, covenant and agreements contained herein shall survive the Closing and remain in full force and effect; provided however, the representations and warranties shall expire on the third anniversary of the date of the last Closing hereunder. No independent investigation of Inspire by Medtronic, its counsel, or any of its agents or employees shall in any way limit or restrict the scope of the representations and warranties made by Inspire in this Agreement.
7.4) Waiver, Discharge, Amendment, Etc. The exercise by either party of any remedy or recourse available to it hereunder shall not deprive such party of any other remedy or recourse available to it under applicable law. Any waiver by either party of a breach of any term of this Agreement shall not be considered as a waiver of any subsequent breach of the same or other terms or condition hereof. This Agreement may be amended by Inspire and Medtronic by mutual action approved by their respective Boards of Directors or their respective officers authorized by such Board of Directors. Any amendment to this Agreement shall be in writing and signed by Inspire and Medtronic.
7.5) Notices. All notices or other communications to a party required or permitted hereunder or under the Certificate of Incorporation, as amended, shall be in writing and shall be delivered personally or by facsimile (receipt confirmed electronically) to such party (or, in the case of an entity, to an executive officer of such party) or shall be sent by a reputable express delivery service or by certified mail, postage prepaid with return receipt requested, addressed as follows:
if to Medtronic to:
Medtronic, Inc.
World Headquarters
000 Xxxxxxxxx Xxxxxxx, X.X.
Xxxxxxxxxxx, XX 00000-0000
Attention: General Counsel
FAX (###) ###-####
with a copy to:
Medtronic, Inc.
World Headquarters
000 Xxxxxxxxx Xxxxxxx, X.X.
Xxxxxxxxxxx, XX 00000-0000
Attention: Vice President and Chief Development Officer
FAX (###) ###-####
if to Inspire to:
0000 Xxxxxxxxx Xxxxxx Xxxxx, Xxxxx 000
Xxxxxxxx Xxxx, XX 00000
ATTN: President and CEO
FAX: (###)-###-####
with a copy to:
Xxxxx Law Offices
00 Xxxxx 0xx Xxxxxx, Xxxxx 0000
Xxxxxxxxxxx, XX 00000
Attn: ####### #####
FAX: (###)-###-####
Any party may change the above-specified recipient and/or mailing address by notice to all other parties given in the manner herein prescribed. All notices shall be deemed given on the day when actually delivered as provided above (if delivered personally or by facsimile) or on the day shown on the return receipt (if delivered by mail or delivery service).
7.6) Public Announcement. Public Announcements shall be governed as set forth in the Investment Agreement.
7.7) Expenses. Except as expressly provided herein, Inspire and Medtronic shall each pay their own expenses incident to this Agreement and the preparation for, and consummation of, the transactions provided for herein.
7.8) Notice of Dispute. The parties shall attempt in good faith to resolve any dispute arising out of or relating to this Agreement promptly by negotiation between executives of each party who have authority to settle the controversy and who are at a higher level of management than the persons with direct responsibility for administration of this Agreement. Either party may give the other party written notice of any dispute not resolved in the normal course of business (“Notice of Dispute”), which Notice of Dispute shall include (i) a statement of that party’s position and a summary of arguments supporting that position, (ii) the dollar amount of the dispute, if known, and the section(s) of the Agreement to which the dispute relates and (iii) the name and title of the executive who will represent that party and of any other person who will accompany the executive. Within 10 days after delivery of the Notice of Dispute, the receiving party shall submit to the other a written response (the “Response to Dispute”). The Response to Dispute shall include (iv) a statement of that party’s position and a summary of arguments including references to any section(s) of the Agreement, if applicable, supporting that position and (v) the name and title of the executive who will represent that party and of any other person who will accompany the executive. Within ten (10) days after delivery of the Response to Dispute, the designated executives of both parties shall meet at a mutually acceptable time and place or by conference telephone, and thereafter as often as they reasonably deem necessary, to attempt to resolve the dispute. All negotiations pursuant to this clause are confidential and shall be treated as compromise and settlement negotiations for purposes of applicable rules of evidence.
7.9) Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Minnesota, without reference to the choice of law principles thereof.
7.10) Titles and Headings; Construction. The titles and headings to articles and sections herein are inserted for the convenience of reference only and are not intended to be a part of or to affect the meaning or interpretation of this Agreement. Inspire acknowledges that Medtronic and Inspire have jointly participated in the negotiation and drafting of this Agreement, and the parties
agree that this Agreement shall be construed without regard to any presumption or other rule requiring construction hereof against the party causing this Agreement to be drafted.
7.11) Benefit. Nothing in this Agreement, expressed or implied, is intended to confer on any person other than the parties hereto or their respective successors or assigns, any rights, remedies, obligations or liabilities under or by reason of this Agreement.
7.12) Counterparts. This Agreement may be executed in one or more counterparts, all of which shall be considered one and the same agreement, and shall become a binding agreement when one or more counterparts have been signed by each party and delivered to the other party. Copies of this Agreement with signatures transmitted by facsimile shall be deemed to be original signed versions of this Agreement.
7.13) Parties in Interest. All representations, covenants and agreements contained in this Agreement by or on behalf of any of the parties hereto shall bind and inure to the benefit of the respective successors and assigns of the parties hereto whether so expressed or not.
7.14) Severability. If any provision of this Agreement is held invalid by a court of competent jurisdiction, the remaining provisions shall nonetheless be enforceable according to their terms. Further, if any provision is held to be overbroad as written, such provision shall be deemed amended to narrow its application to the extent necessary to make the provision enforceable according to applicable law and shall be enforced as amended.
7.15) No Joint Venture. Nothing contained in this Agreement shall be deemed to create a joint venture, partnership, agency or similar endeavor between the parties hereto. Each party shall act solely as an independent contractor and neither party shall have any power or authority to direct or indirectly bind or act on behalf of the other.
[Remainder of page intentionally left blank]
IN WITNESS WHEREOF, each of the parties has caused this Agreement to be executed in the manner appropriate to each, effective as of the date first above written.
|
||
|
| |
|
| |
|
/s/ Xxxxxxx X. Xxxxxxx | |
|
By: Xxxxxxx X. Xxxxxxx | |
|
Its: President & CEO | |
|
| |
|
| |
|
MEDTRONIC, INC. | |
|
| |
|
| |
|
/s/ Xxxxxx X. Xxxxx | |
|
By: |
Xxxxxx X. Xxxxx |
|
Its: |
|
Exhibit A: Assigned Patents
US Patent/Application |
|
Title |
5,158,080 |
|
Muscle tone |
International Patents |
|
None |
5,540,731 |
|
Method and apparatus for pressure detecting and treating obstructive airway disorders |
International Patents |
|
DE69532740D1 20040429 |
|
|
DE69532740T2 20050428 |
|
|
EP0702979B1 20040324 |
|
|
EP0702979A3 19970319 |
|
|
EP0702979A2 19960327 |
5,540,732 |
|
Method and apparatus for impedance detecting and treating obstructive airway disorders |
International Patents |
|
DE69529951D1 20030424 |
|
|
DE69529951T2 20040205 |
|
|
EP0702977B1 20030319 |
|
|
EP0702977A3 19970319 |
|
|
EP0702977A2 19960327 |
|
|
JP3733555B2 20060111 |
|
|
JP3733555B2 20060111 |
|
|
JP8224318A 19960903 |
5,540,733 |
|
Method and apparatus for detecting and treating obstructive sleep apnea |
International Patents |
|
None |
5,549,655 |
|
Method and apparatus for synchronized treatment of obstructive sleep apnea |
International Patents |
|
DE69526767D1 20020627 |
|
|
DE69526767T2 20030102 |
|
|
DE69532514D1 20040304 |
|
|
DE69532514T2 20041014 |
|
|
EP1175919B1 20040128 |
|
|
EP1 175919A1 20020130 |
|
|
EP1277491A1 20030122 |
|
|
EP0706808B1 20020522 |
|
|
EP0706808A1 19960417 |
|
|
JP3733556B2 20060111 |
|
|
JP3733556B2 20060111 |
|
|
JP9187521A 19970722 |
5,591,216 |
|
Method for treatment of sleep apnea by electrical stimulation |
International Patents |
|
DE69629238D1 20030904 |
|
|
DE69629238T2 20040527 |
|
|
DE69636883D1 20070322 |
|
|
EP1306104B120070131 |
|
|
EP1306104A3 20040811 |
|
|
EP1306104A2 20030502 |
|
|
EP0743076B1 20030730 |
|
|
EP0743076A1 19961120 |
6,251,126 |
|
Method and apparatus for synchronized treatment of obstructive sleep apnea |
International Patents |
|
None |
6,269,269 |
|
Method and apparatus for synchronized treatment of obstructive sleep apnea |
International Patents |
|
None |
Exhibit B: Licensed Patents
|
|
WO9750049A1 19971231 |
6,021,352 |
|
Diagnostic testing methods and apparatus for implantable therapy devices |
International Patents |
|
AT301490T 20050815 |
|
|
AU727327B2 20001207 |
|
|
AU3649797A 19980114 |
|
|
CA2259155C 20020409 |
|
|
CA2259155A1 19971231 |
|
|
DE69733954D1 20050915 |
|
|
DE69733954T2 20060518 |
|
|
DK0917486T3 20051212 |
|
|
EP0917486B1 20050810 |
|
|
EP0917486A1 19990526 |
|
|
ES2246516T3 20060216 |
|
|
JP0000000000A 20040617 |
|
|
JP11514557T 19991214 |
|
|
WO9749455A1 19971231 |
6,099,479 |
|
Method and apparatus for operating therapy system |
International Patents |
|
AT216906T 20020515 |
|
|
AU768822B2 20040108 |
|
|
AU1836001A 20010412 |
|
|
AU3503197A 19980114 |
|
|
CA2258812C 20020409 |
|
|
CA2258812A1 19971231 |
|
|
DE69712369D1 20020606 |
|
|
DE69712369T2 20021128 |
|
|
EP0957983B1 20020502 |
|
|
EP0957983A1 19991124 |
|
|
JP2003190303A 20030708 |
|
|
JP11514554T 19991214 |
|
|
WO9749452A1 19971231 |
6,641,542 |
|
Method and apparatus to detect and treat sleep respiratory events |
International Patents |
|
CA2445709A1 20021107 |
|
|
EP1385425A1 20040204 |
|
|
JP2004529707T 20040930 |
|
|
WO2002087433A9 20030327 |
|
|
WO2002087433A1 20021107 |
6,731,984 |
|
Method for providing a therapy to a patient involving modifying the therapy after detecting an onset of sleep in the patient, and implantable medical device embodying same |
International Patents |
|
None |
6,752,765 |
|
Method and apparatus for monitoring heart rate and abnormal respiration |
International Patents |
|
CA2429237A1 20020523 |
|
|
DE60035719D1 20070906 |
|
|
EP1337296B1 20070725 |
|
|
EP1337296A1 20030827 |
|
|
JP2004513713T 20040513 |
|
|
WO2002040096A1 20020523 |
6,964,641 |
|
Implantable medical device with sleep disordered breathing monitoring |
International Patents |
|
CN1897872A 20070117 |
|
|
EP1706023A1 20061004 |
|
|
WO2005065536A1 20050721 |
20030120161 |
|
Automatic pressure range and sensitivity adjustment |
International Patents |
|
None |
20040059240 |
|
Method and apparatus to detect and treat sleep respiratory events (Impedance Sensing for OSA) |
International Patents |
|
None |
5,215,082 |
|
Implantable apnea generator with ramp on generator |
International Patents |
|
DE69212520D1 19960905 |
|
|
DE69212520T2 19970306 |
|
|
EP0507580B1 19960731 |
|
|
EP0507580A3 19930324 |
|
|
EP0507580A2 19921007 |
5,233,983 |
|
Method and apparatus for apnea patient screening |
International Patents |
|
None |
5,238,006 |
|
Apnea stimulation lead |
International Patents |
|
None |
5,281,219 |
|
Multiple stimulation electrodes |
International Patents |
|
None |
5,483,969 |
|
Method and apparatus for providing a respiratory effort waveform for the treatment of obstructive sleep apnea |
International Patents |
|
None |
5,522,862 |
|
Method and apparatus for treating obstructive sleep apnea |
International Patents |
|
DE69527903D1 20021002 |
|
|
DE69527903T2 20030528 |
|
|
EP0702978B1 20020828 |
|
|
EP0702978A3 19980506 |
|
|
EP0702978A2 19960327 |
|
|
JP3684514B2 20050817 |
|
|
JP8224317A 19960903 |
6,132,384 |
|
Sensor, method of sensor implant and system for treatment of respiratory disorders |
International Patents |
|
None |
6,572,543 |
|
Sensor, method of sensor implant and system for treatment of respiratory disorders |
International Patents |
|
AT276793T 20041015 |
|
|
AU3580097A 19980114 |
|
|
CA2258289A1 19971231 |
|
|
DE69730842D1 20041028 |
|
|
DE69730842T2 20050929 |
|
|
EP0917485B1 20040922 |
|
|
EP0917485A1 19990526 |
|
|
ES2229374T3 20050416 |
|
|
JP11514555T 19991214 |
|
|
JP3249826B2 20020121 |
|
|
US6132384A 20001017 |
|
|
WO9749454A1 19971231 |
20040176809 |
|
Method and apparatus for modifying delivery of a therapy in response to onset of sleep |
International Patents |
|
CA2549489A1 20050707 |
|
|
DE60203902D1 20050602 |
|
|
DE60203902T2 20060524 |
|
|
EP1395336B1 20050427 |
|
|
EP1395336A2 20040310 |
|
|
EP1706174A2 20061004 |
|
|
WO2002100482A3 20030320 |
|
|
WO2002100482A2 20021219 |
|
|
WO2005061046A3 20070524 |
|
|
WO2005061046A2 20050707 |
Exhibit B-1: IDEA Disclosures
IDEA Disclosure P0028998.00 |
|
Submitted by Xxxx Xxxxxxxxxxxxxx |
IDEA Disclosure P0029000.00 |
|
Submitted by Xxxx Xxxxxxxxxxxxxx |
IDEA Disclosure P0029002.00 |
|
Submitted by Xxxx Xxxxxxxxxxxxxx |
IDEA Disclosure P0029003.00 |
|
Submitted by Xxxx Xxxxxxxxxxxxxx |
IDEA Disclosure P0029004.00 |
|
Submitted by Xxxx Xxxxxxxxxxxxxx |
IDEA Disclosure P0030197.00 |
|
3063 Stimulation Lead — Inventor is Xxxx Xxxxx, MDT employee |
Exhibit C
Technical Information
3063 Lead
BOM |
|
Item Type |
|
Description |
|
License |
|
Transfer |
|
|
|
|
Tunneling Tool: believe this is 210459, 800283, 168025, 404214, 210171. |
|
|
|
|
198244001 |
|
Manual |
|
MANUAL-TECH,LEAD,PERIPHERAL NERVE,3063(EUROPEAN CLINICAL) |
|
X |
|
X |
210459001 |
|
Catheter |
|
GUIDE-TUNNELING,SST.3990/3990A,PASSIVATED |
|
X |
|
X |
800283001 |
|
Catheter |
|
GUIDE-TUNNELING,WEDGE TIP |
|
X |
|
X |
168025001 |
|
Miscellaneous Component |
|
RUBBER-SILICONE,MOLDING,BIOCOMP,HARDNESS 45-55 SHORE A |
|
X |
|
X |
404214001 |
|
Ferrule |
|
COLLET ASSY-4322 (Sensitive information will be redacted) |
|
X |
|
X |
210171001 |
|
Miscellaneous Xxxxxxxxx |
|
XXX-XXXXXXXX,XXXXXX,.000XXX0.00XX,0000 (Sensitive information will be redacted) |
|
X |
|
X |
152753001 |
|
Cable |
|
XXXXX-XX.0 XXXX,XXXXXXXX,0000 |
|
X |
|
X |
141889001 |
|
XXX |
|
XXX-STERILE PACKAGE,UNIVERSAL,LONG |
|
X |
|
X |
119943002 |
|
Cover |
|
COVER-TRAY,INNER,STERILE PACKAGE,UNIVERSAL |
|
X |
|
X |
101045001 |
|
Sheet |
|
SHEET-VINYL,CLEAR WIDTH,LENGTH, AND TFIK PER PO |
|
X |
|
X |
119951001 |
|
Closure |
|
LID-OUTER TRAY,STANDARD LEAD |
|
X |
|
X |
119942001 |
|
Tray |
|
TRAY-OUTER,STERILE PACKAGE,LONG UNIVERSAL |
|
X |
|
X |
101045001 |
|
Sheet |
|
SHEET-VINYL,CLEAR WIDTH,LENGTH, AND THK PER PO |
|
X |
|
X |
119941002 |
|
Tray |
|
TRAY-INNER,STERILE PACKAGE,LONG UNIVERSAL |
|
X |
|
X |
101045001 |
|
Sheet |
|
SHEET-VINYL,CLEAR WIDTH,LENGTH, AND THK PER PO |
|
X |
|
X |
194117004 |
|
Label |
|
LABEL-BAR CODE,BLANK,THERMAL TRANSFER, 2.00 IN. X 0.50 IN. |
|
X |
|
X |
082059002 |
|
XXX |
|
XXX-FNL PKG,UNVRSL,LNG,APS,STD |
|
X |
|
X |
193364002 |
|
Label |
|
LABEL-SEAL,TEAR TAB,MEDTRONIC |
|
X |
|
X |
119957001 |
|
Box |
|
CARTON-FOLDING,SHIPPING(WHITE) |
|
X |
|
X |
187947002 |
|
Sheet |
|
SHEET-INSTRUCTION,OPENING,LEADTRAY |
|
X |
|
X |
220290001 |
|
Label |
|
TEMPLATE-LABEL SET,STIM GENERIC,(DIE B) |
|
X |
|
X |
‘82012003 |
|
Form |
|
FORM-REGISTRATION,DEVICE TRACKING(LEAD/CATHETER) (Sensitive information will be redacted) |
|
X |
|
X |
82731001 |
|
Sheet |
|
SHEET-ADDENDUM,DIATHERMY,PHYSICIAN MANUAL |
|
X |
|
X |
502668001 |
|
Lead |
|
LEAD ASSY-NERVE,PERIPHERAL,SELF SIZING, 3063(45CM,3MM CUFF) (Sensitive information will be redacted) |
|
X |
|
X |
206360001 |
|
Electrode |
|
ELECTRODE-TAB,HALF (Sensitive information will be redacted) |
|
X |
|
X |
141588001 |
|
Label |
|
LABEL-SERIAL NO |
|
X |
|
X |
105872001 |
|
Sleeve |
|
ANCHORING SLEEVE-DOUBLE SUTURE (Sensitive information will be redacted) |
|
X |
|
X |
3063 Lead
Model No. |
|
Document |
|
Description |
|
License |
|
Transfer |
3063 |
|
600000 |
|
Project Charter |
|
X |
|
X |
3063 |
|
600001 |
|
Project Initiation Form |
|
X |
|
X |
3063 |
|
600002 |
|
Concept Phase Design Review Minutes System Design Plan or re-titled as 3063 |
|
X |
|
X |
3063 |
|
600003 |
|
Program Plan |
|
X |
|
X |
3063 |
|
600004 |
|
Marketing Plan (Sensitive information will be redacted) |
|
X |
|
X |
3063 |
|
600005 |
|
Risk Analysis |
|
X |
|
X |
3063 |
|
600006 |
|
Standards Assessment |
|
X |
|
X |
3063 |
|
600007 |
|
Planning and Specification Phase Design Review Minutes |
|
X |
|
X |
3063 |
|
600008 |
|
Design Verification Plan (Sensitive information will be redacted) |
|
X |
|
X |
3063 |
|
600009 |
|
Design Verif. Report (Sensitive information will be redacted) |
|
X |
|
X |
3063 |
|
600010 |
|
Clinical Manag. Plan |
|
X |
|
X |
3063 |
|
600011 |
|
Clinical Protocol (Sensitive information will be redacted) |
|
X |
|
X |
3063 |
|
600012 |
|
Clinical Readiness Review |
|
X |
|
X |
3063 |
|
600015 |
|
Labeling Validation Report (manuals/labels) Material/Supplier Qualification Plan/Report |
|
X |
|
X |
3063 |
|
600016 |
|
(NA) |
|
X |
|
X |
3063 |
|
600017 |
|
Supplier / Materials Assessment |
|
X |
|
X |
3063 |
|
600018 |
|
Classification of Characteristics Report |
|
X |
|
X |
3063 |
|
600019 |
|
Design FMEA |
|
X |
|
X |
3063 |
|
600020 |
|
User FMEA |
|
X |
|
X |
3063 |
|
600023 |
|
Mfg Process Characterization |
|
X |
|
X |
3063 |
|
600024 |
|
Mfg Equip Installation Plan/Report |
|
X |
|
X |
3063 |
|
600025 |
|
Reliability Assessment |
|
X |
|
X |
3063 |
|
600026 |
|
Safety Assessment |
|
X |
|
X |
3063 |
|
600027 |
|
Technical File/Design Dossier (for CE xxxx) |
|
X |
|
X |
3063 |
|
600028 |
|
Regulatory Submissions |
|
X |
|
X |
3063 |
|
600029 |
|
Regulatory Approvals for Clinical |
|
X |
|
X |
3063 |
|
600030 |
|
Standards Compliance Report& Certificates |
|
X |
|
X |
3063 |
|
600031 |
|
Development Phase Design Review Minutes (Sensitive information will be redacted) |
|
X |
|
X |
3024 IPG
BOM |
|
Item Type |
|
Description |
|
License |
|
Transfer |
120110001 |
|
Label Software |
|
JETFORM FILE NEURO IPG |
|
X |
|
|
502040002 |
|
IPG |
|
IPG ASSY-INSPIRE II,3024,K |
|
X |
|
|
404827004 |
|
EMA |
|
EMA ASSY-INSPIRE II,3024,T/K(DESICCANT) |
|
X |
|
|
404754001 |
|
Shield Assy |
|
LH SHIELD ASSY-(IN-LINE)ITREL 3,7425(EMA),T |
|
X |
|
|
211088001 |
|
Shield |
|
SHIELD HALF-LEFT,ITREL 3 |
|
X |
|
|
101291001 |
|
Alloy |
|
TITANIUM-SHEET,BEAD BLASTED,.012+-,0005THK, GRD 1 |
|
X |
|
|
210329001 |
|
Bead |
|
BEADS-STAINLESS STEEL |
|
X |
|
|
103725001 |
|
Insulator |
|
INSULATOR-BATTERY,ITREL 3,(PET,POLYESTER W/ADHES.), 1.3X1.48 |
|
X |
|
|
101060009 |
|
Film |
|
STRIP-POLYESTER,.005THK TS=25000PSI,W AND LG PER PO |
|
X |
|
|
404752001 |
|
Battery |
|
BATTERY ASSEMBLY-IPG,7425(EMA),T |
|
X |
|
|
161177001 |
|
Battery |
|
XXXX-XXXXXXX/XXXXXXX XXXXXXXX,0.0X,0.0XX@0XX,0.00XX.000XX0.0 |
|
X |
|
|
199004001 |
|
Power Source |
|
QA REQT-POWER CELLS AND BATTERIES |
|
X |
|
|
211212002 |
|
Contact |
|
CONTACT-B PLUS,T-BLOCK,XXXXX,PLATED |
|
X |
|
|
211212001 |
|
Contact |
|
CONTACT-B PLUS,T-BLOCK,XXXXX |
|
X |
|
|
210862002 |
|
Contact |
|
CONTACT-BLOCK,7960,PLATED |
|
X |
|
|
153212010 |
|
Tubing |
|
TUBING-PTFE,TRANSPARENT .042 ODX.020X.004 LIGHT WALL |
|
X |
|
|
181637005 |
|
Hybrid |
|
XXXXXX-XXXXXXXXXXXXXXXXX,XXXXXXX XX,0000 |
|
X |
|
X |
404787002 |
|
Shield Assy |
|
RH SHIELD ASSY-ITREL 3,7425(EMA),T |
|
X |
|
|
404786001 |
|
Shield Assy |
|
SHIELD SUBASSEMBLY-RH,7425(EMA)T |
|
X |
|
|
206588001 |
|
Shield |
|
SHIELD XXXX/XXXXXX XX,0000 |
|
X |
|
|
211087004 |
|
Shield |
|
SHIELD HALF-RIGHT HAND,ITREL 3 (WITH HOLES AND RECESS)TALL U |
|
X |
|
|
103772001 |
|
Insulator |
|
INSULATOR CUP-ITREL 3,POLYPROPYLENE (INCLUDED FEATURE) |
|
X |
|
|
171093001 |
|
Adhesive |
|
MOLDING-POLYPROPYLENE RESIN HARDNESS 8696 ROCKWELL R |
|
X |
|
|
210862002 |
|
Contact |
|
CONTACT-BLOCK,7960,PLATED |
|
X |
|
|
140089002 |
|
Feedthru |
|
FEEDTHRU ASSY-TOPHAT,8081 |
|
X |
|
|
140081002 |
|
Feedthru |
|
TERMINAL-FEEDTHRU.FLAT TOP.IPGTITANIUM |
|
X |
|
|
151071001 |
|
Contact |
|
CONTACT-DISK,GOLD-PLATED XXXXX,.073-.075 DIAX .025-.027 |
|
X |
|
|
168188001 |
|
Preform |
|
PREFORM-SOLDER,GOLD/TIN,.070 DIA X .002 THK (0108564A006) |
|
X |
|
|
211048004 |
|
Desiccant |
|
DESICCANT-ITREL 3,CLEANED |
|
X |
|
|
211048002 |
|
Desiccant |
|
DESICCANT-ITREL 3 |
|
X |
|
|
163021002 |
|
Powder |
|
POWDER-DESICCANT,7960 |
|
X |
|
|
163022001 |
|
Polymer |
|
RUBBER-SILICONE,LSR,2 PART |
|
X |
|
|
101293001 |
|
Wire |
|
WIRE-UNINSULATED,8081,WIREBOND |
|
X |
|
|
101292003 |
|
Adhesive |
|
ADHESIVE-ELECT MOD COMP,RESIN,1 GALLON |
|
X |
|
|
101292004 |
|
Adhesive |
|
ADHESIVE-ELECT MOD COMP,CATALYST,1 GALLON |
|
X |
|
|
210635002 |
|
Fastener |
|
XXXXXXXX-XXXXXX,XXXXXXXX,X0,0 XXXXX |
|
X |
|
|
0000 XXX
BOM |
|
Item Type |
|
Description |
|
License |
|
Transfer |
101038008 |
|
Alloy |
|
TITANIUM-SHT,ARGON ANNEAL,.010THK,+-.001,GRD1 |
|
X |
|
|
210624020 |
|
Radiopaque |
|
XXXXXX-XXXXX,XXXXXXXXXX,XXXXXXX XX,XXX,0000 |
|
X |
|
|
101231001 |
|
Sheet |
|
SHEET-TUNGSTEN,PER FED STD 151ANSI-B46.1,ASTM-E92 |
|
X |
|
|
410274001 |
|
Grommet |
|
SEAL ASSY-COMPRESSION,7074/75 |
|
X |
|
|
104605001 |
|
Grommet |
|
GROMMET-SPLIT,SI RBR,.090 ODX 0.30IDX.103T,GRV=.1500DX.068W |
|
X |
|
|
168588001 |
|
Polymer |
|
MOLDING-SILICONE RUBBER 2-PARTMEDICAL GRD,HARDNESS 30-40 DUR |
|
X |
|
|
104585001 |
|
Ring |
|
RING-COMPRESSION,SILICON .140ODX.100IDX.060THK |
|
X |
|
|
153191014 |
|
Tubing |
|
TUBING-SILICONE RUBBER,TRANS .140 ODX.100X.015 WALL,DUR 50A |
|
X |
|
|
110941002 |
|
Screw |
|
SCREW-MACH,SET,HEX SKT,CUP PT TITANIUM,2-56X.125,CLASS 2A |
|
X |
|
|
101227001 |
|
Alloy |
|
TITANIUM ALLOY-ROD,TS=135K PSI.125 TO 4.5 IN OD,(6AL-4V) |
|
X |
|
|
149460001 |
|
Connector |
|
CONNECTOR MODULE-ITREL 3,OPEN SLOTS |
|
X |
|
|
168166003 |
|
Polymer |
|
RESIN-POLYETHER URETHANE,YEL,74 SHORE D,5000PSI,200% ELONG |
|
X |
|
|
149121001 |
|
Connector |
|
CONNECTOR BODY-IMPL,SLIMLINE 8420/21 |
|
X |
|
|
101031004 |
|
Sheet |
|
TI-GRD4,TS=80KSI,AVAIL FORM SHEET/STRIP/PLATE/BAR/BILLETS |
|
X |
|
|
101031003 |
|
Sheet |
|
TI-GRD3,TS=60KSI, AVAIL FORM SHEET/STRIP/PLATE/BAR/BILLETS |
|
X |
|
|
101031002 |
|
Sheet |
|
TI-GRD2,TS=50KSI,AVAIL FORM SHEET/STRIP/PLATE/BAR/BILLETS |
|
X |
|
|
149120001 |
|
Connector |
|
CONNECTOR BODY-IMPL,SLMLN,8420 |
|
X |
|
|
101031004 |
|
Sheet |
|
TI-GRD4,TS=80KSI,AVAIL FORM SHEET/STRIP/PLATE/BAR/BILLETS |
|
X |
|
|
101031003 |
|
Sheet |
|
TI-GRD3,TS=60KSI, AVAIL FORM SHEET/STRIP/PLATE/BAR/BILLETS |
|
X |
|
|
101031002 |
|
Sheet |
|
TI-GRD2,TS=50KSI,AVAIL FORM SHEET/STRIP/PLATE/BAR/BILLETS |
|
X |
|
|
117988001 |
|
Seal |
|
SEAL-INNER,DUAL BIPOLAR |
|
X |
|
|
168588002 |
|
Silicon |
|
MOLDING-SILICONE RUBBER,2-PARTMEDICAL GRD,HARDNESS 45-55 DUR |
|
X |
|
|
104597001 |
|
Seal |
|
OUTER SEAL-CONNECTOR |
|
X |
|
|
168588002 |
|
Silicon |
|
MOLDING-SILICONE RUBBER,2-PARTMEDICAL GRD,HARDNESS 45-55 DUR |
|
X |
|
|
168171003 |
|
Adhesive |
|
ADHESIVE-RTV,SILICONE RUBBER,1 PART,TRANSLUCENT,6 OZ(170 G) |
|
X |
|
|
168079001 |
|
Coating |
|
COATING-PARYLENE-C |
|
X |
|
|
171506991 |
|
Dadet |
|
ENCAPSULANT-EPOXY RESIN KIT,SIZE 1 OZ ENCAP AND HARDENER |
|
X |
|
|
152284005 |
|
Wire |
|
WIRE-UNINS,NIOBIUM,.015DIA +-.001, TS=18,000 |
|
X |
|
|
168064002 |
|
Primer |
|
PRIMER-GAMA-METHACRYLOXYPROPYLTRIMETHOXYSILANE,CLEAR LIQUID |
|
X |
|
|
3024 IPG
BOM |
|
Item Type |
|
Description |
|
License |
|
Transfer |
19679001 |
|
Tray |
|
TRAY-PACKAGING,IPG,OUTER,THERA,7940 |
|
X |
|
|
101271001 |
|
Film |
|
FILM-PETG COPOLYESTER,PKG,UNCOATED |
|
X |
|
|
50007001 |
|
Tray |
|
TRAY-PACKAGING,INNER |
|
X |
|
|
119708001 |
|
Lid |
|
LID-PACKAGING,IPG,OUTER,THERA |
|
X |
|
|
101168002 |
|
Sheet |
|
SHEET-POLYETHYLENE FIBER,.0073THK.CTD,XXXXXX 18B |
|
X |
|
|
119707001 |
|
Lid |
|
LID-PACKAGING,IPG,INNER,THERA |
|
X |
|
|
101168002 |
|
Sheet |
|
SHEET-POLYETHYLENE FIBER,.0073THK.CTD,XXXXXX 18B |
|
X |
|
|
800242001 |
|
Wrench |
|
WRENCH-HEX #2 |
|
X |
|
|
101029006 |
|
Alloy |
|
SST-420 TYPE1,AVAILABLE FORM BAR/WIRE |
|
X |
|
|
119718002 |
|
Box |
|
BOX-SHELF,IPG,6.63 X 5.25 X 2.44 |
|
X |
|
|
119968001 |
|
Cushion |
|
FOAM-INSERT,7223 |
|
X |
|
|
119724003 |
|
Bag |
|
POUCH-IPG,LITERATURE,FOLDING |
|
X |
|
|
100477001 |
|
Film |
|
FILM-POLYETHYLENE,LOW DENSITY DIMENSIONS PER PO |
|
X |
|
|
197615001 |
|
Manual |
|
MANUAL-TECH,MODEL 3024,PHYSICIAN’S MANUAL,EN |
|
X |
|
X |
197552001 |
|
Manual |
|
MAUNAL-TECH,3024,INSPIRE,PATIENT,US |
|
X |
|
X |
186193004 |
|
Form |
|
FORM-REGISTRATION,IPG SYSTEM |
|
X |
|
X |
103334001 |
|
Bag |
|
POUCH-PLASTIC,ID CARD,ITREL IIITREL 3,TRANSFORM REGIST FORM |
|
X |
|
X |
187380025 |
|
Transformer |
|
TRANSFORM-PATIENT ID CARD,CARDIOMYOSTM,4710,E/EF/EG/ES/EI/EN |
|
X |
|
X |
187222025 |
|
Card |
|
XXXX-XXXXXXX XX,XXXXX,0000/00 E/EF/EG/ES/EI/EN |
|
X |
|
X |
194642001 |
|
Label |
|
LABEL SET-UNIVERSAL,SMALL,TACHY |
|
X |
|
X |
193364002 |
|
Label |
|
XXXXX-XXXX,XXXX XXX,XXXXXXXXX |
|
X |
|
X |
00000000 |
|
Xxxxxxxx |
|
XXXXXXXX-XXXXX |
|
X |
|
X |
L169 |
|
Inspire L169 |
|
Inspire L169 IC Specification (Design files, IC Verilog/Verifault VHDL simulations) |
|
X |
|
X |
L169 |
|
Inspire L169 IC |
|
Layout Files |
|
X |
|
X |
L169 |
|
Inspire L169 IC |
|
Verification and Validation Plans / Reports |
|
X |
|
X |
L169 |
|
Inspire L169 IC |
|
Inspire L169 IC Test Specification |
|
X |
|
X |
181637 |
|
Inspire Hybrid |
|
Electrical Specification |
|
X |
|
X |
601601 |
|
Inspire Hybrid |
|
Electrical Schematic, Inspire Hybrid |
|
X |
|
X |
2125229 |
|
Inspire Hybrid |
|
Inspire Hybrid Test Specification |
|
X |
|
X |
3024 IPG
Model No. |
|
Document |
|
Description |
|
License |
|
Transfer |
3024 |
|
2841-3079 |
|
0000 Xxxxxx XXXX |
|
X |
|
|
3024 |
|
2841-3104 |
|
Upper Airway Stimulation (UAS) System Hazard Analysis |
|
X |
|
|
3024 |
|
3024-3000 |
|
Reliability Development Plan for UAS Inspire (II)IPG, Model 3024. |
|
X |
|
|
3024 |
|
3024-3004 |
|
Chargeback for UAS Project |
|
X |
|
|
3024 |
|
3024-3006 |
|
Initial Hazard Analysis |
|
X |
|
|
3024 |
|
3024-3006 |
|
Upper Airway Stimulation System Hazard Analysis |
|
X |
|
|
3024 |
|
3024-3008 |
|
UAS Commitment Phase Review Summary |
|
X |
|
|
3024 |
|
3024-3009 |
|
Upper Airway Stimulation (UAS) Development Plan |
|
X |
|
|
3024 |
|
3024-3010 and 3024-3051 |
|
Memo Xxxx Xxxxx from Xxxxxx Xxxxxxxx Aug 2, 1998 and 3024- “Upper Airway IPG” |
|
X |
|
|
3024 |
|
3024-3011 |
|
Product Specification Ventor IPG Model 3024 |
|
X |
|
|
3024 |
|
3024-3012 |
|
Patent Review for IPG UAS |
|
X |
|
|
3024 |
|
3024-3013 |
|
Business Plan “Obstructive Sleep Apnea Upper Airway Stimulation” |
|
X |
|
|
3024 |
|
3024-3018 |
|
Cstim Slew Rate Measurements |
|
X |
|
|
3024 |
|
3024-3020 |
|
STIM Waveform (Recharge Investigation) |
|
X |
|
|
3024 |
|
3024-3024 |
|
Medical Advisory Board Meeting, July 16, 1997, Summary |
|
X |
|
|
3024 |
|
3024-3035 |
|
ECO Release Model 3024 Inspire II Product Specification |
|
X |
|
|
3024 |
|
3024-3035 |
|
Inspire II Product Specification (083553) |
|
X |
|
|
3024 |
|
3024-3038 |
|
Memo to Xxxx Xxxxxxxxxx from Xxxx Xxxxxxxxxxxxxx Oct 25, 1994 Preliminary 60hz Testing of the 4322 Sensor and the Phase I System |
|
X |
|
|
3024 |
|
3024-3153 |
|
Memo to Xxxx Xxxxxxxxxx, Xxxx Xxxxx from Xxxx Xxxxxxxxxxxxxx, October 25, 1995 “L169 Verilog Verification Stimulations” with Test Plan |
|
X |
|
|
3024 |
|
3024-3155 |
|
Memo to Xxxx Xxxxxxxxxx from Xxxx Xxxxxxxxxxxxxx |
|
X |
|
|
3024 |
|
3024-3157 |
|
083553 Model 3024 Inspire II IPG Product Specification Rev A |
|
X |
|
|
3024 |
|
3024-3161 |
|
Qual Plan: Qualification of Inspire II IPG (Model 3024) (L169-004) |
|
X |
|
|
3024 |
|
3024-3162 |
|
Verification Plan: Inspire II (Model 3024) Hybrid Test Plan, Detection Algorithm Specific L169 Verification Plan (L169-004) |
|
X |
|
|
3024 |
|
3024-3162-1 |
|
Test Report: Memo to Inspire II Team from Xxxx Xxxxxxxxxxxxxx “Functionality of First Hybrids” |
|
X |
|
|
3024 |
|
3024-3178 |
|
Design Verification of the Rev 2 Hybrid (Inspire II IPG) Status |
|
X |
|
|
3024 |
|
3024-3201 |
|
Inspire II Manufacturing Plan Rev B |
|
X |
|
|
3024 |
|
3024-3204 |
|
Memo to Distribution from Xxx Xxxx “Inspire II Phase 2 CDR Minutes” |
|
X |
|
|
3024 |
|
|
|
1) Memo to File from Xxxx Xxxxxxxxxxxxxx “Summary of Rev 2 Hybrid Evaluation (L169 IC/lnspire II, Model 3024) |
|
X |
|
|
3024 |
|
|
|
2) Memo to Inspire II Team from Xxxx Xxxxxxxxxxxxxx “Testing of the Analog Front End and Vref” |
|
X |
|
|
3024 |
|
|
|
3) Memo to Inspire II from Xxxx Xxxxxxxxxxxxxx “Status of L169 Following Trip to Xxxxx-Xxx |
|
X |
|
|
0000 XXX
Model No. |
|
Document |
|
Description |
|
License |
|
Transfer |
3024 |
|
3024-3228 |
|
4) Memo to Xxxx Xxxxxxxxxxxxxx from Xxx Xxxx “Inspire II Network/topo Changes Reply” |
|
X |
|
|
3024 |
|
|
|
5) Memo to Distribution from Xxx Xxxx “Inspire II Phase 2 CDR Minutes” |
|
X |
|
|
3024 |
|
|
|
6) Memo to Xxxx Xxxxxxxxxx/Xxxx Xxxxxxxx from Xxxx Xxxxxxxxxxxxxx “Design Verification of the Rev 2 Hybrid (Inspire II IPG) |
|
X |
|
|
3024 |
|
3024-3229 |
|
Lab Notebook Inspire II Hybrid Verification Rev 2 March 1996 (Xxxx Xxxxxxxxxxxxxx ) |
|
X |
|
|
3024 |
|
3024-3235 |
|
Lab Notebook Documentation and Qualification of the Inspire II Stimulus Tester (Labview) |
|
X |
|
|
3024 |
|
3024-3249 |
|
Memo to Xxxx Xxxxxxxx from Xxxx Xxxxxxxxxxxxxx “Inspire II Hybrid Evaluations Summary (Rev 3) |
|
X |
|
|
3024 |
|
3024-3257 |
|
Lab Notebook UAS Algorithm Verification April, 1994 (Xxxx Xxxxxxxxxxxxxx) |
|
X |
|
|
3024 |
|
3024-3288 |
|
Inspire II Product Transfer Plan Rice Creek to ESTC Rev A |
|
X |
|
|
3024 |
|
3024-3289 |
|
Inspire II Manufacturing Plan rev C |
|
X |
|
|
3024 |
|
3024-3291 |
|
Memo to Inspire II Team from Xxxx Xxxxxxxxxxxxxx “Longevity Calculations” |
|
X |
|
|
3024 |
|
3024-3301 |
|
Memo to Project File from Xxxx Xxxxxxxxxxxxxx “Rev 4 Telemetry Frequency” |
|
X |
|
|
3024 |
|
3024-3316 |
|
Memo to Distribution from Xxxx Xxxxxxxxxxxxxx “Inspire II Telemetry Frequency” |
|
X |
|
|
3024 |
|
3024-3321 |
|
Qual Plan: QE%-115: H1637-003 and L169-001 for Inspire II (Micro-Rel L169-001 Qual) |
|
X |
|
|
3024 |
|
3024-3330 |
|
Hybrid Operations Development Portfolio: Phase II of the Inspire I Project (Renamed Inspire II) September 14, 1995 |
|
X |
|
|
3024 |
|
3024-3345 |
|
Qual Plan: System Testing and Production Qualification of Model 3024 Inspire II IPG Nov 13, 1997 (L169-004) |
|
X |
|
|
3024 |
|
3024-3349 |
|
Report: Inspire II Model 3024 Hybrid Test Report, Detection Algorithm Specific |
|
X |
|
|
3024 |
|
3024-3350 |
|
Memo to Inspire II Team from Xxxx Xxxxxxxxxxxxxx “Net DC Measurements” [Draft] (L169-004) |
|
X |
|
|
3024 |
|
3024-3351 |
|
Memo to Inspire II Team from Xxxx Xxxxxxxxxxxxxx “Inspire II Rev 4 Design Verification Report Summary” |
|
X |
|
|
3024 |
|
3024-3353 |
|
L169 Verification Plan Rev F |
|
X |
|
|
3024 |
|
3024-3353 |
|
Micro-Rel L169 Verification Plan (169-004) |
|
X |
|
|
3024 |
|
3024-3354 |
|
Hybrid Inspire II L169-4 CDR October 28, 1996 |
|
X |
|
|
3024 |
|
3024-3355 |
|
ECO Specification 215124 Model 3024 Inspire II IPG Test Specification Rev A |
|
X |
|
|
3024 |
|
3024-3357 |
|
Micro-Rel Validation Plan: Inspire II Electronic Module Manufacturing Processes Validation Document |
|
X |
|
|
3024 |
|
3024-3358 |
|
Micro-Rel Report Memo to Distribution from Xxxx Xxxxx “Inspire II Electronic Module Mechanical Qualification Acceptance” |
|
X |
|
|
3024 |
|
3024-3362 |
|
Inspire II Hybrid XXXX |
|
X |
|
|
0000 XXX
Model No. |
|
Document |
|
Description |
|
License |
|
Transfer |
3024 |
|
3024-3363 |
|
Micro-Rel Report Memo to Distribution from Xxxx Xxxxx “Inspire II Electronic Module Mechanical Qualification” |
|
X |
|
|
3024 |
|
3024-3376 |
|
Micro-Rel Qual Report “Electrical Qualification of the Inspire II Hybrid and L169 IC (L169-001) |
|
X |
|
|
3024 |
|
3024-3377 |
|
Medical Advisory Board Meeting Total System Implant Project July 16, 1997 |
|
X |
|
|
3024 |
|
3024-3383 |
|
Inspire II Model 3024 Rev 4 Design Verification Lab Book Dec ‘96-Jan ‘97 |
|
X |
|
|
3024 |
|
3024-3387 |
|
Inspire II L169 Rev 4 Qualification Test Data June-Aug ‘97 |
|
X |
|
|
3024 |
|
3024-3388 |
|
Report: System Testing and Production Qualification of Model 3024 Inspire II IPG August ‘97 (L169-004) |
|
X |
|
|
3024 |
|
3024-3392 |
|
Design Verification Report Inspire II (Model 3024) Hybrid Test Report, Detection May 97 Algorithm Specific (L169-004) |
|
X |
|
|
3024 |
|
3024-3393 |
|
Memo to Xxx Xxxxxxxxx/Xxxx Xxxxxxxx from Xxxx Xxxxxxxxxxxxxx “Inspire II AGC Change for Rev 5 |
|
X |
|
|
3024 |
|
3024-3403 |
|
Report “Electrical Qualification of the Inspire II Hybrid and L169IC with Corrections (L169-003) |
|
X |
|
|
3024 |
|
3024-3404 |
|
Memo to Project File from Xxxx Xxxxxxxxxxxxxx Oct 13, 1997 L169 Rev 5 (Inspire II ) Review Meetings |
|
X |
|
|
3024 |
|
3024-3408 |
|
Characterization Delta Analysis” Sept 18, 1997 [3404] Memo to Distribution from Xxxx Xxxxx “Correction to Inspire II Delta Analysis Report |
|
X |
|
|
3024 |
|
3024-3411 |
|
Memo to Inspire II Team from Xxxx Xxxxxxxxxxxxxx Sept 29, 1997 “Inspire II Telemetry Status” |
|
X |
|
|
3024 |
|
3024-3412 |
|
2) Report Inspire II Electronic Module Process Validation Document |
|
X |
|
|
3024 |
|
3024-3416 |
|
System Testing and Production Qualification of Model 3024 Inspire II IPG, L169-007 |
|
X |
|
|
3024 |
|
3024-3417 |
|
Inspire II (Model 3024) Hybrid Test Plan (Design Verification) L169-007 |
|
X |
|
|
3024 |
|
3024-3422 |
|
Memo to Inspire II Development Team from Xxxx Xxxxxxxx “Inspire II Fix-it List |
|
X |
|
|
3024 |
|
3024-3439 |
|
Memo to Project File from Xxxx Xxxxxxxxxxxxxx Inspire II Design Summary: Rev-006/-007 May, 1998 Memo: Design Verification and Design Qualification of the Rev 7 L169 Inspire II IPG |
|
X |
|
|
3024 |
|
3024-3446 |
|
Design Review Meeting Minutes (Inspire System Review), July 30, 1998 |
|
X |
|
|
3024 IPG
Model No. |
|
Document |
|
Description |
|
License |
|
Transfer |
3024 |
|
3024-3451 |
|
Model 3024 Inspire II UAS IPG Safety Requirements. (Updated UAS System Hazard Analysis) |
|
X |
|
|
3024 |
|
3024-3452 |
|
Inspire II, Upper Airway System, Safety Assessment |
|
X |
|
|
3024 |
|
3024-3453 |
|
Inspire II Model 0000 XXXX |
|
X |
|
|
3024 |
|
3024-3454 |
|
Model 3024 Inspire II Customer Use FMEA |
|
X |
|
|
3024 |
|
3024-3456 |
|
Report: System Testing and Production Qualification of Model 3024 Inspire II IPG Sept. 1998 (L169-007) |
|
X |
|
|
3024 |
|
3024-3457 |
|
Micro-Rel Product Qualification Plan (H1637-003& L169- 001) and (H1637-004 and L169-007) |
|
X |
|
|
3024 |
|
3024-3458 |
|
Hybrid Test Report (Design Verification) L169-007 |
|
X |
|
|
3024 |
|
3024-3460 |
|
AIMD Conformity Assessment Checklist/Essential Requirements (Initial Draft) |
|
|
|
|
3024 |
|
3024-3462 |
|
Design Verification Test Data,Inspire II (3024) (L169-007) |
|
X |
|
|
3024 |
|
3024-3463 |
|
4322 dp/dt Sensor Capsule: Inspire II System Bias Voltage Drift Test Plan |
|
|
|
|
3024 |
|
3024-3465 |
|
Comparison of Inspire I vs. Inspire II |
|
X |
|
|
3024 |
|
3024-3466 |
|
Materials Availability for the Inspire II System |
|
X |
|
|
3024 |
|
3024-3470 |
|
Inspire II System Phase I Review |
|
X |
|
|
3024 |
|
3024-3473 |
|
Early Product Description, UAS IPG System |
|
X |
|
|
3024 |
|
3024-3475 |
|
Investigators Meeting, October 16, 1995 |
|
X |
|
|
3024 |
|
3024-3479 |
|
Micro-Rel Inspire II Verification Results |
|
X |
|
|
3024 |
|
3024-3480 |
|
Net DC Measurements on Inspire II |
|
X |
|
|
3024 |
|
3024-3481 |
|
Itrel 3 Packaging (and Sterilization) Qualification |
|
X |
|
|
3024 |
|
3024-3482 |
|
ITREL 3 Model 7425 Reliability Assessment (Failure Rate Prediction) 1100-94-161 |
|
X |
|
|
3024 |
|
3024-3483 |
|
Itrel 3 Process File List |
|
X |
|
|
3024 |
|
3024-3484 |
|
Final Customer Use FMEA for Itrel 3 System |
|
X |
|
|
3024 |
|
3024-3485 |
|
Itrel 0 XXX XXXX |
|
X |
|
|
3024 |
|
3024-3486 |
|
Itrel 3 EMA FMEA |
|
X |
|
|
3024 |
|
3024-3487 |
|
Itrel 3 IPG EMA Product Qualification Test Plan and Report |
|
X |
|
|
3024 |
|
3024-3488 |
|
Itrel 3 Mechanical Qualification Plan and Report |
|
X |
|
|
3024 |
|
3024-3489 |
|
Risk Assessment for the Upper Airway Stimulation (UAS) System |
|
X |
|
|
3024 |
|
3024-3491 |
|
Inspire Controlled Release Plan, September 15, 1998 |
|
X |
|
|
3024 |
|
3024-3492 |
|
Itrel 3 EMC Qualification Plans and Reports |
|
X |
|
|
3024 |
|
3024-3493 |
|
Inspire II System Manuals Audit |
|
X |
|
|
3024 |
|
3024-3494 |
|
Inspire II Clinical Protocol and Overview |
|
X |
|
|
3024 |
|
3024-3496 |
|
Inspire II IDE Submission, September 25, 1998 |
|
X |
|
|
3024 |
|
3026-3223 |
|
Inspire I Product Specification (083543) |
|
X |
|
|
3024 |
|
3026-3326 |
|
0000/0000 Xxxxxx XXXX |
|
X |
|
|
3024 |
|
|
|
Latest ECO of Specs and Drawings |
|
X |
|
|
3024 |
|
215214 |
|
Inspire II IPG Final Test Specification |
|
X |
|
|
4322 Pressure Senior Lead
BOM Part |
|
Description |
|
License |
|
Transfer |
404180001 |
|
Inspire dp/dt Sensor (original design) |
|
X |
|
X |
404180 |
|
Mechanical Specification |
|
X |
|
X |
180808003 |
|
Hybrid |
|
X |
|
X |
180808 |
|
Electrical Specification |
|
X |
|
X |
083444/083846 |
|
Product Specification |
|
X |
|
X |
140058002 |
|
Feedthru |
|
X |
|
X |
140058 |
|
Mechanical Specification |
|
X |
|
X |
180779001 |
|
Hybrid |
|
X |
|
X |
200945 |
|
Miscellaneous Document |
|
X |
|
X |
200428 |
|
Test Specification |
|
X |
|
X |
200068 |
|
Electrical Specification |
|
X |
|
X |
180779 |
|
Electrical Specification |
|
X |
|
X |
200112 |
|
Product Specification |
|
X |
|
X |
200068 |
|
Electrical Specification |
|
X |
|
X |
200070 |
|
Product Specification |
|
X |
|
X |
200113 |
|
Miscellaneous Document |
|
X |
|
X |
201173, 201172 |
|
Test Specifications |
|
X |
|
X |
117600001 |
|
Connector |
|
X |
|
X |
168626001 |
|
Miscellaneous Component |
|
X |
|
X |
124132 |
|
Inspire dp/dt crystal specification |
|
X |
|
X |
108999 |
|
Inspire dp/dt crystal assembly |
|
X |
|
X |
605488 |
|
Inspire dp/dt D46 final acceptance |
|
X |
|
X |
0107074, 0104778 |
|
Inspire dp/dt D46 DHF, specs, and design files (layout, schematic) |
|
X |
|
X |
2507077 |
|
Inspire dp/dt D46 reticles/mask |
|
X |
|
X |
605658 |
|
Inspire dp/dt D46 Visual Specification |
|
X |
|
X |
|
|
Inspire dp/dt Sensor (collaboration design) |
|
X |
|
X |
Collab - new |
|
Inspire dp/dt Sensor DHF (specifications, verification and validation plans / reports) |
|
X |
|
X |
Collab - new |
|
Inspire dp/dt Sensor DMR (BOM, electrical and mechanical drawings) |
|
X |
|
X |
Collab - new |
|
Inspire dp/dt Test System Specification |
|
X |
|
X |
Collab - new |
|
Inspire dp/dt Test System Mechanical and Electrical Drawings |
|
X |
|
X |
Collab - new |
|
Inspire dp/dt Test System verification and validation plans and reports |
|
X |
|
X |
Collab - new |
|
Inspire dp/dt Test System Software specification |
|
X |
|
X |
Collab - new |
|
Inspire dp/dt Test System Software source code |
|
X |
|
X |
Collab - new |
|
Inspire dp/dt Test System Software Verification and Validation Plans/Reports |
|
X |
|
X |
Collab - new |
|
Inspire dp/dt Test System User Manual |
|
X |
|
X |
4322T00 |
|
Package Specification |
|
X |
|
|
193176017 |
|
Label |
|
X |
|
X |
186341001 |
|
Form |
|
X |
|
X |
197755001 |
|
Manual |
|
X |
|
X |
192339001 |
|
Label |
|
X |
|
X |
119562001 |
|
Box |
|
X |
|
X |
4322 Pressure Senior Lead
BOM Part |
|
Description |
|
License |
|
Transfer |
119562 |
|
Package Specification |
|
X |
|
X |
502608002 |
|
Lead (Sensitive information will be redacted) |
|
X |
|
X |
119551001 |
|
Closure |
|
X |
|
|
101168002 |
|
Sheet |
|
X |
|
|
119858001 |
|
Tray |
|
X |
|
|
119858 |
|
Package Specification |
|
X |
|
|
119431005 |
|
Disk |
|
X |
|
|
119550001 |
|
Closure |
|
X |
|
|
141566001 |
|
Label |
|
X |
|
|
4322 Pressure Sensor Lead
Model No. |
|
Document |
|
Description |
|
License |
|
Transfer |
4322 |
|
4322-A002 |
|
4322 Product Description and Development Plan |
|
X |
|
X |
4322 |
|
4322-B004 |
|
4322 Sensor and Test Requirements: Frequency Response and Pressure Levels (Sensitive information will be redacted) |
|
X |
|
X |
4322 |
|
4322-B005 |
|
ESD and Cautery Testing on the 4322 Sensor/Lead |
|
X |
|
X |
4322 |
|
4322-C004 |
|
Design Review 4322 Comments |
|
X |
|
X |
4322 |
|
4322-C007 |
|
Electrical Test Requirements for the 4322 Respiratory Pressure Sensor |
|
X |
|
X |
4322 |
|
4322-C011 |
|
4322 Test Specifications (Supersedes Memo: Electrical Test Requirements for 4322 Respiratory Pressure Sensor, Dec. 20, 1994 |
|
X |
|
X |
4322 |
|
4322-C018 |
|
Test Setup Files and Associated Files for Capsule and Lead Testing Inspire I Devices (Model 4322) Qualification Plan (Sensitive information will be redacted) |
|
X |
|
X |
4322 |
|
4322-C024 |
|
Chronic Monitor: Week #12 - 4322 Data Results (First Two Canines) |
|
X |
|
X |
4322 |
|
4322-C025 |
|
Model 4322 Sleep Apnea Lead Qualification Test Plan (Sensitive information will be redacted) |
|
X |
|
X |
4322 |
|
4322-C025A |
|
Model 4322 Sleep Apnea Lead Qualification Test Plan Rev A (Sensitive information will be redacted) |
|
X |
|
X |
4322 |
|
4322-C027 |
|
Sterilization of Model 4322 Lead (Sensitive information will be redacted) |
|
X |
|
X |
4322 |
|
4322-C033 |
|
Observations from the 4322 Human Cadaver Study (2/09/96) |
|
X |
|
X |
4322 |
|
4322-C034 |
|
My Notes from the Cadaver Lab |
|
X |
|
X |
4322 |
|
4322-C040 |
|
4322T Human Acute Study Qualification Report |
|
X |
|
X |
2032 Inspire Patient Programmer
BOM Part |
|
Item Type |
|
Description |
|
License |
|
Transfer |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
8840 Physician Programmer
BOM Part |
|
Item Type |
|
Description |
|
|
|
|
411326003 |
|
Miscellaneous Component |
|
TELEMETRY MODULE SUBASSEMBLY- PROGRAMMER |
|
X |
|
X |
177848002 |
|
Closure |
|
HOUSING-BOTTOM,TELEMETRY,8840 WITH EMI SPRAYCOAT |
|
X |
|
X |
177949002 |
|
Antenna |
|
ANTENNA-TELEMETRY MODULE,8840 VARNISHED |
|
X |
|
X |
411214005 |
|
Miscellaneous Component |
|
ASSEMBLY - PWB, 8840 TELEMETRY MODULE |
|
X |
|
X |
170681001 |
|
Shield |
|
SHIELD-TM, H FIELD |
|
X |
|
X |
183764001 |
|
Tape |
|
FOAM TAPE -DIECUT SET, TM |
|
X |
|
X |
411327002 |
|
Miscellaneous Component |
|
REEL ASSEMBLY-PROGRAMMER, 8840 |
|
X |
|
X |
170394002 |
|
Cable |
|
CABLE-TELEMETRY MODULE,POLYPROPYLENE PRIMARIES INSULATION |
|
X |
|
X |
177910001 |
|
Strain Relief |
|
STRAIN RELIEF-CABLE |
|
X |
|
X |
77850001 |
|
Cable |
|
XXXX-XXXXX, XXX,0000 |
|
X |
|
X |
177851001 |
|
Cable |
|
REEL-CABLE, BOTTOM,8840 |
|
X |
|
X |
149785001 |
|
Connector |
|
HOUSING-CONNECTOR, 1.25MM |
|
X |
|
X |
149786001 |
|
Connector |
|
CONTACT-CONNECTOR, 1.25MM |
|
X |
|
X |
170395002 |
|
Flex |
|
CABLE-FLEX,PCB-TM,COPPER STRENGTH MEMBER,.025-.030. |
|
X |
|
X |
177911001 |
|
Strain Relief |
|
STRAIN RELIEF-REEL |
|
X |
|
X |
161367001 |
|
Battery |
|
BATTERY - LITHUIM, POLY-CARBONMONOFLUORIDE, 3 VOLT, BR1225 |
|
X |
|
X |
177853001 |
|
Miscellaneous Component |
|
RETAINER-CORD,8840 |
|
X |
|
X |
186034001 |
|
Label |
|
COLOR CHIP-SLATE MEDIUM XXXX |
|
X |
|
X |
177849001 |
|
Closure |
|
HOUSING-TOP,TELEMETRY,8840 |
|
X |
|
X |
186034001 |
|
Label |
|
COLOR CHIP-SLATE MEDIUM XXXX |
|
X |
|
X |
220344001 |
|
Label |
|
LABEL-TELEMETRY MODULE,8840 |
|
X |
|
X |
186034001 |
|
Label |
|
COLOR CHIP-SLATE MEDIUM XXXX |
|
X |
|
X |
110778002 |
|
Screw |
|
SCREW-PCB,8840,#2-28X3/8 |
|
X |
|
X |
220371001 |
|
Label |
|
LABEL-BATTERY COMPARTMENT,INSIDE,8840 |
|
X |
|
X |
8840 Physician Programmer
BOM Part |
|
Item Type |
|
Description |
|
|
|
|
177836001 |
|
Cover |
|
COVER-BATTERY,8840 |
|
X |
|
X |
186034001 |
|
Label |
|
COLOR CHIP-SLATE MEDIUM XXXX |
|
X |
|
X |
119000008 |
|
Bag |
|
BAG-POLYETHYLENE,5WX12LGX.003THK |
|
X |
|
X |
100477001 |
|
Film |
|
FILM-POLYETHYLENE,LOW DENSITY DIMENSIONS PER PO |
|
X |
|
X |
165145001 |
|
Tape |
|
TAPE-SEALING,BOX,TRANSPARENT W=36MM |
|
X |
|
X |
168836001 |
|
Oil |
|
GREASE-PTFE |
|
X |
|
X |
350209001 |
|
Miscellaneous Assembly |
|
CARTON-SHELF,CORRUGATED,PHY PROGRAMMER,8840 |
|
X |
|
X |
101170101 |
|
Sheet |
|
SHEET-FIBERBOARD CORR, SGL WALLMIN BURSTING TEST=200LBS/SQ IN |
|
X |
|
X |
161076001 |
|
Battery |
|
BATTERY-ALKALINE MN,1.5V,2.7MAH@300MA,SIZE AA FLAT CONTACT |
|
X |
|
X |
198311001 |
|
Manual |
|
MANUAL-PHYSICIAN,PROGRAMMER,PLATFORM,8840 |
|
X |
|
X |
182599001 |
|
Sheet |
|
CARD-QUICK REFERENCE,PHYSICIAN PROGRAMMER,8840 |
|
X |
|
X |
170192001 |
|
Box |
|
CASE-CARRYING,8840 |
|
X |
|
X |
220352001 |
|
Label |
|
XXXXX XXX-XXXXXXX, XXX, XXXXXXXXX, 0000 |
|
X |
|
X |
170285001 |
|
Die Cutter |
|
DIE XXX-XXXXX XXX, XXX-XXXXXXXXX, 0000 |
|
X |
|
X |
633708002 |
|
Firmware |
|
FIRMWARE FORMAT, LABEL, SHIPPING, PROGRAMMER, 8840(DOMESTIC), Rx Only |
|
X |
|
X |
165145001 |
|
Tape |
|
TAPE-SEALING,BOX,TRANSPARENT W=36MM |
|
X |
|
X |
198960001 |
|
Magnet |
|
INSERT - PLACEMENT, PROGRAMMER AND MAGNET, 8840 |
|
X |
|
X |
Software |
|
Drivers/base s/w |
|
8840 Itrel 3 driver level source software and Itrel 3 application/source code. |
|
X |
|
X |
Software DHR |
|
Software DHF |
|
8840 Itrel 3 driver and application DHR reference |
|
X |
|
X |
Software Tools |
|
S/W tools |
|
Software tools sufficient to compile and build the Itrel 3 drivers and application |
|
X |
|
X |
4328 RTD Research Programmer (Inspire II Research Programmer)
BOM Part |
|
Item |
|
Description |
|
License with MDT |
|
Transfer with |
4328RTD |
|
DMR |
|
|
|
X |
|
X |
7432AE Physician Programmer/ 3052 Memmod (Inspire II Physician Programmer - very outdated)
BOM Part |
|
Item |
|
Description |
|
License for use |
|
Transfer Inspire, beyond |
4328RTD |
|
DMR |
|
|
|
X |
|
X |
3032 Patient Programmer DHF
Model No. |
|
Document |
|
Description |
|
License for use Mfg |
|
Transfer with |
3032 DHF |
|
|
|
Right of Reference to 3031 lnterstim Patient Programmer |
|
X |
|
X |
8840 Physician Programmer DHF
Model No. |
|
Document |
|
Description |
|
License |
|
Transfer |
8840 DHF |
|
|
|
Right of Reference to 8840 Physician Programmer |
|
X |
|
X |
8840 DHF |
|
|
|
Right of Reference to 8848 Physician Programmer Software |
|
X |
|
X |
4328 RTD Research Programmer DHF
Model No. |
|
Document |
|
Description |
|
License |
|
Transfer |
4328 RTD Research Programmer DHF |
|
|
|
|
7432AE Physician Programmer DHF
Model |
|
Document |
|
Description |
|
License for use |
|
Transfer |
3052 |
|
3052-3001 |
|
3052 Product Specification #083482-001, Rev A |
|
X |
|
X |
3052 |
|
3052-3029 |
|
3052 Memory Module Software Hazard List, Analysis & Report |
|
X |
|
X |
3052 |
|
3052-3030 |
|
3052 Memmod Planning Phase Review Report |
|
X |
|
X |
3052 |
|
3052-3032 |
|
3052 Memmod Prototype Phase Review Report |
|
X |
|
X |
3052 |
|
3052-3054 |
|
3052 Memmod Concept Phase Review Report |
|
X |
|
X |
3052 |
|
3052-3169 |
|
UAS Model 3052 Memory Module & Model 2841 & 3024 IPG Software Development, Configuration Mgmt, & Verification & Validation Plans |
|
X |
|
X |
3052 |
|
3052-3206 |
|
Release of Memmod Model 3052 Revision NDR03 |
|
X |
|
X |
3052 |
|
3052-3209 |
|
Inspire I System for the Treatment of Obstructive Sleep Apnea |
|
X |
|
X |
3052 |
|
3052-3225 |
|
3052 Version Description Document Software Specification #217364-001, Rev B |
|
X |
|
X |
3052 |
|
3052-3314 |
|
Changes in the 3052 Memmod for Inspire II |
|
X |
|
X |
3052 |
|
3052-3315 |
|
3052 Memory Module Software Test Plan, Rev B |
|
X |
|
X |
3052 |
|
3052-3317 |
|
3052 Memmod Traceability Map, Rev B |
|
X |
|
X |
3052 |
|
3052-3361 |
|
Completion of Functional Testing Phase for 3052 Memmod |
|
X |
|
X |
3052 |
|
3052-3410 |
|
3052 Memmod Version Description Document Software Specification #217364 |
|
X |
|
X |
3052 |
|
3052-3450 |
|
Model 3052 Version NDR05 Test Report |
|
X |
|
X |
PATENT ASSIGNMENT
WHEREAS, Medtronic, Inc. (“Assignor”), is the owner of the United States and foreign patents and patent applications identified on the attached Exhibit A; and
WHEREAS, Inspire Medical Systems, Inc. (“Assignee”), desires to acquire the entire right, title and interest in and to the United States and foreign patents and patent applications identified on the attached Exhibit A and in and to the inventions described and claimed therein (hereinafter “Patents”);
In exchange for good and valuable consideration, the receipt of which is hereby acknowledged, Assignor hereby assigns to Assignee all of Assignor’s right, title and interest in and to the Patents, and all rights to seek and collect damages and other relief for infringement of the Patents, and all proceeds thereof.
This Agreement may be executed in one or more counterparts, all of which shall be considered one and the same agreement. The signatures from each counterpart may be combined with a copy of the Agreement to constitute the entire Agreement.
|
MEDTRONIC, INC. | |
|
| |
|
| |
|
By: |
/s/ |
|
Name: |
|
|
Title: |
|
|
| |
|
| |
STATE OF |
) | |
|
) ss. | |
COUNTY OF |
) |
On this day of , 2007, before me, a notary public in and for said county, appeared of Medtronic, Inc., the person who signed this instrument, who acknowledged that he or she signed it as a :free act on behalf of said company with authority to do so.